UroGen Pharma Stock (NASDAQ:URGN)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$12.20

52W Range

$10.60 - $20.70

50D Avg

$12.95

200D Avg

$14.84

Market Cap

$502.42M

Avg Vol (3M)

$596.38K

Beta

1.12

Div Yield

-

URGN Company Profile


UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

203

IPO Date

May 04, 2017

Website

URGN Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 23Dec 22Dec 21
Jelmyto$82.71M$64.36M$48.04M

Fiscal year ends in Dec 23 | Currency in USD

URGN Financial Summary


Dec 23Dec 22Dec 21
Revenue$82.71M$64.36M$48.04M
Operating Income$-65.54M$-79.04M$-92.29M
Net Income$-102.24M$-109.16M$-110.82M
EBITDA$-65.54M$-78.03M$-75.00M
Basic EPS-$-4.79$-4.96
Diluted EPS-$-4.79$-4.96

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q2 24Aug 13, 24 | 3:05 PM
Q1 24May 13, 24 | 12:00 AM
Q4 23Mar 14, 24 | 8:13 PM

Peer Comparison


TickerCompany
VIGLVigil Neuroscience, Inc.
SRRKScholar Rock Holding Corporation
PRTCPureTech Health plc
IKNAIkena Oncology, Inc.
EWTXEdgewise Therapeutics, Inc.
ERASErasca, Inc.
INBXInhibrx Biosciences, Inc.
GBIOGeneration Bio Co.
VACCBarinthus Biotherapeutics plc
TYRATyra Biosciences, Inc.
KRONKronos Bio, Inc.
CNTBConnect Biopharma Holdings Limited
CCCCC4 Therapeutics, Inc.
PEPGPepGen Inc.
XLOXilio Therapeutics, Inc.
TARAProtara Therapeutics, Inc.
OVIDOvid Therapeutics Inc.
CELCCelcuity Inc.
MACKMerrimack Pharmaceuticals, Inc.
ELVNEnliven Therapeutics, Inc.
CMPXCompass Therapeutics, Inc.
ELYMEliem Therapeutics, Inc.